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Dengue  viruses  (DENV)  currently  infect  approximately  400  million  people  each  year  causing  millions  to
seek  care  and  overwhelming  the  health  care  infrastructure  in endemic  areas.  Vaccines  to  prevent  dengue
and therapeutics  to  treat dengue  are  not  currently  available.  The  efﬁcacy  of  the most  advanced  candidate
vaccine  against  symptomatic  dengue  in  general  and  DENV-2  in particular  was  much  lower  than  expected,
despite  the ability  of the vaccine  to induce  neutralizing  antibody  against  all four DENV  serotypes.  Because
seroconversion  to the  DENV  serotypes  following  vaccination  was  thought  to  be  indicative  of  induced
protection,  these  results  have  made  it more  difﬁcult  to assess  which  candidate  vaccines  should  or  should
not be evaluated  in  large  studies  in  endemic  areas.  A  dengue  human  infection  model  (DHIM)  could  be
extremely  valuable  to down-select  candidate  vaccines  or therapeutics  prior  to  engaging  in  efﬁcacy  trials
in endemic  areas.  Two  DHIM  have  been  developed  to  assess  the  efﬁcacy  of live attenuated  tetravalent
(LATV)  dengue  vaccines.  The  ﬁrst model,  developed  by the Laboratory  of  Infectious  Diseases  at  the  U. S.
National  Institutes  of Health,  utilizes  a modiﬁed  DENV-2  strain DEN230.  This  virus  was  derived  from
the  DENV-2  Tonga/74  that  caused  only  very  mild  clinical  infection  during  the outbreak  from  which  it  was
recovered.  DEN230  induced  viremia  in  100%,  rash  in 80%,  and  neutropenia  in 27% of the  30  subjects  to
whom  it  was  given.  The  Walter  Reed  Army  Institute  of  Research  (WRAIR)  is  developing  a  DHIM  the goal
of  which  is  to identify  DENV  that  cause  symptomatic  dengue  fever.  WRAIR  has  evaluated  seven  viruses
and  has  identiﬁed  two  that  meet  dengue  fever  criteria.  Both  of  these  models  may  be  very  useful  in the
evaluation  and  down-selection  of  candidate  dengue  vaccines  and  therapeutics.
ublis©  2015  The  Authors.  P
. Dengue epidemiology
Dengue has become the most important mosquito-borne virus
n the world. Recent reports estimate as many as 390 million
nfections annually, with one in four of those infections causing
ymptomatic illness [1]. Dengue is a member of the Flaviviridae
amily and is transmitted by Aedes mosquitoes, most commonly
edes aegypti. The increased geographical spread of both the
ector and the virus over the past several decades, unprece-
ented population growth, and uncontrolled urbanization have
ed to the resurgence of dengue throughout the tropical and
ubtropical regions of the world [2]. There are four serotypes
f dengue, all capable of causing the full spectrum of disease.
 Clinicaltrial.gov registration NCT01931176 and NCT02021968.
∗ Corresponding author at: Johns Hopkins Bloomberg School of Public Health, 624
 Broadway, Room 217, Baltimore, MD 21205, United States. Tel.: +1 410 614 4736.
E-mail address: apdurbin@verizon.net (A.P. Durbin).
ttp://dx.doi.org/10.1016/j.vaccine.2015.09.052
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article 
/).hed  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Symptomatic dengue illness can range from a self-limited febrile
illness accompanied by myalgia, arthralgia, rash, neutropenia, and
thrombocytopenia (dengue fever) to severe disease resulting in
vascular leak syndrome and shock [3]. Although infection with one
DENV serotype is thought to induce long-lived protection against
symptomatic illness with that serotype, it provides only short-term
protection against the other DENV serotypes [4–6]. While severe
disease can occur following a primary DENV infection, the most
important risk factor for the development of severe dengue is the
presence of pre-existing immunity to a heterotypic DENV serotype
at the time of secondary DENV infection [7–9]. The higher risk of
severe disease with a second, heterotypic DENV is thought to be
caused by a phenomenon known as antibody-dependent enhance-
ment of infection (ADE) in which non-neutralizing, heterotypic
antibody binds to DENV and allows it to enter Fc receptor-bearing
cells leading to enhanced virus production from a greater number
of infected cells [10–12]. This, in turn, leads to an increase in
viremia, which has been shown to correlate with more severe
dengue disease [13–15]. Interestingly, this increased risk of severe
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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isease is rarely observed with sequential third and fourth DENV
nfections [16,17], suggesting that sequential DENV infection may
nduce an increasingly broad immune response to protect against
evere disease with a third or fourth DENV infection.
. Rationale for a dengue human infection model
Because of the risk of severe disease with partial immunity to
engue, it is believed that an effective DENV vaccine must protect
gainst all four DENV serotypes. Currently, a licensed vaccine for
engue is not available, however, there are several vaccine can-
idates in early and advanced clinical development. Of these, the
anoﬁ Pasteur candidate CYDTM is furthest along and has completed
ultiple efﬁcacy trials. CYDTM is a live attenuated tetravalent vac-
ine comprised of four chimeric viruses in which the prM and E
roteins of each of DENV replace those of the yellow fever 17D vac-
ine virus. The vaccine has completed a Phase 2b trial in Thailand
nd two Phase 3 trials, one in Asia and one in Latin America
18–20]. The vaccine induced neutralizing antibody to all four DENV
erotypes in more than 95% of vaccinated subjects, however the
verall efﬁcacy of the vaccine was highly variable, owing to wide
ariation in protection against individual serotypes, and protec-
ion in those who were dengue-naïve at vaccination compared to
hose who were dengue-experienced. The overall efﬁcacy against
ymptomatic dengue was only 30.2% in the Phase 2b trial (not sig-
iﬁcant), with no protection against DENV-2. Overall efﬁcacy was
6.5% in the Phase 3 trial in Asia but protection against DENV-2 and
rotection in those who were dengue-naïve at vaccination were
ot signiﬁcant. Overall efﬁcacy in the Phase 3 trial in Latin Amer-
ca was 60.8% but protection in those who were dengue-naïve at
accination was not signiﬁcant. The variable efﬁcacy observed in
hese trials despite the reported mean level of neutralizing anti-
odies has made vaccine developers less conﬁdent in the predictive
alue of the neutralizing antibody titer. The safety implications of
his decision is signiﬁcant since candidate vaccines offering only
artial protection could potentially put clinical trial participants in
ndemic areas at risk for more severe disease should they become
nfected with DENV months or years after receipt of the vaccine.
or this reason, a dengue human infection model could provide an
xtremely useful tool for the down-selection of candidate dengue
accines or dengue therapeutics.
. History of the dengue human infection model (DHIM)
A DHIM that minimizes harm to volunteers while providing
ccurate representation of wild-type dengue infection would be
 valuable research tool that could help guide which products ulti-
ately go on to Phase 2b and Phase 3 trials. Indeed, the utility of
his approach to studying dengue infections has been recognized
ince the early 20th century when volunteers were intentionally
nfected with dengue to characterize various aspects of the infec-
ion. A summary of previous DHIM studies is included in Table 1.The
ajority of these studies were done prior to or during World War
I at a time when the incidence of DENV infections was still emerg-
ng [4,21–25]. For this reason, the subjects did not have DENV
ntibody at the time of infection and the potential risk of severe
isease was minimal. From these studies, investigators were able
o determine the nature of the dengue ﬁlterable agent (a virus),
he vector of dengue (Aedes mosquitoes), the external incubation
eriod of the virus, and the presence of multiple serotypes of the
irus. These studies also enabled investigators to characterize the
linical and laboratory manifestations of a primary dengue infec-
ion. In addition, early candidate dengue vaccines were developed
nd/or evaluated for protection against challenge or developed for
se as challenge viruses [26–30]. Prior to the ability to culture the3 (2015) 7075–7082
virus, investigators transmitted dengue from one infected person
to another using the natural Aedes mosquito vector [25,26].
4. Clinical and laboratory manifestations of dengue
Infection with dengue virus most commonly manifests as an
asymptomatic infection or undifferentiated febrile illness. Recent
reports estimate approximately 100 million symptomatic infec-
tions (reported) and nearly 300 million asymptomatic or mildly
symptomatic infections (unreported) occur annually [1]. More-
over, in endemic areas, the proportion of children seroconverting
over one transmission season was  5–29%, demonstrating the large
burden of asymptomatic or unrecognized infections [31]. These
data demonstrate that fortunately most dengue infections do not
present with classic dengue fever or severe dengue. Among those
that do become symptomatic, the vast majority develop a febrile
illness categorized by WHO  guidelines as dengue fever [32]. Fol-
lowing initial exposure, symptoms typically manifest within 3
to 7 days at which point individuals may  develop fever, myal-
gia, headache, photophobia and nausea. More speciﬁc to dengue
infection are the occurrence of arthralgia, maculopapular rash, and
retro-orbital pain. Physical exam may  reveal hepatomegaly in chil-
dren, or evidence of minor hemorrhagic sequelae, such as petechiae
in select cases [33]. Imaging studies may  show minor asymp-
tomatic pericardial, peritoneal, or pleural effusions during dengue
fever.
Along with its characteristic clinical syndrome, dengue infection
has also been shown to cause a number of characteristic distur-
bances in hematologic and liver function tests. Notably, during the
initial febrile period, thrombocytopenia, leukopenia, and moder-
ate transaminase elevations have been consistently described [33].
Leukopenia, secondary to a decline in polymorphonuclear cells, was
ﬁrst described as a hallmark feature of the disease at the turn of
the 20th century when some of the earliest hematological features
of the disease were described [34,22]. Patients with dengue also
demonstrate thrombocytopenia, which can be severe as platelet
counts commonly dropping below 20,000 L−1 [33]. Elevation in
liver transaminases during dengue infection is not uncommon
with higher elevations (>10-fold) observed in more severe dengue
[35,36]. Platelet, leukocyte, and transaminase aberrations, how-
ever, typically recover rapidly upon symptomatic resolution [33].
5. Dengue infection model
The Laboratory of Infectious Diseases (LID) at the National
Institutes of Health has evaluated numerous live attenuated
monovalent and tetravalent DENV candidate vaccines as part of
its dengue vaccine development program. Because of the poor
efﬁcacy of CYDTM against DENV-2, despite its ability to induce
a signiﬁcant mean level of DENV-2 neutralizing antibody, the
LID developed a DHIM to evaluate the protective efﬁcacy of its
live attenuated tetravalent (LATV) candidate vaccine TV003 [37]
against challenge with DENV-2. The DENV-1, DENV-3, and DENV-4
components of TV003 are attenuated by one or more 30 nucleotide
deletions in the 3′ UTR. The DENV-2 component of TV003 is a
chimeric virus in which the prM and E proteins of DEN430 (the
DENV-4 component of TV003) are replaced by those of DENV-2
NGC. rDEN2/430 is the most attenuated of the four vaccine
components, inducing detectable viremia in only 5% of vaccine
recipients and seroconversion in 76% [37]. The ideal DHIM would
induce objective, reproducible endpoints with sufﬁcient frequency
that statistically signiﬁcant protection could be determined using a
smaller number of subjects. In addition, if the model could produce
these endpoints without inducing signiﬁcant illness, the risk to
volunteers could be minimized and the studies may  be performed
C.P. Larsen et al. / Vaccine 33 (2015) 7075–7082 7077
Table  1
Dengue human infection model studies (1900–2015).
Lead author Year Number of subjects Location Areas of investigation
Graham [21] 1902 6 Lebanon, Syria Vector identiﬁcation, etiology
Ashburn [22] 1907 4 Philippines Vector identiﬁcation, etiology
Cleland [23] 1919 20 Australia Viral culture, viral tropism
Siler  [24] 1926 47 Philippines Vector identiﬁcation, vector EIP, infectious period, natural history
Simmons  [25] 1931 80 USA Vector identiﬁcation, culture, infectious dose, pathology
Sabin  [4] 1952 >216 USA Immunology, Passaged LADV
Wisseman [28] 1966 4 USA Passaged LADV challenge studies
Fujita  [47] 1969 10 Japan Effects of administration of DENV-1 and YF together
Statler [44] 2008 12 USA Evaluation of DENV challenge strains, Ultrasound-based
diagnosticsMammen [30] 2014
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IP, extrinsic incubation period; LADV, live attenuated dengue vaccine; LATV, live a
s outpatient studies, reducing the overall cost and allowing for
ore volunteers to be enrolled.
Investigators at the LID evaluated numerous live recombinant
ENV vaccine candidates in rhesus macaques to characterize their
ttenuation phenotype and determine if they should be further
valuated in human clinical trials [38]. One such virus was derived
rom a DENV-2 isolate recovered from the 1974 dengue outbreak
n the Paciﬁc island of the Kingdom of Tonga. This outbreak was
otable for having a low attack rate, low incidence of viremia,
nd low incidence of hemorrhagic complications [39]. The atten-
ation strategy used to develop this virus as a candidate DENV-2
accine was to introduce a 30 nucleotide deletion in the 3′ UTR
o create DEN230  [40]. This same strategy successfully atten-
ated DENV-1 and DENV-4 viruses for consideration as vaccine
andidates [38,41,42]. However, pre-clinical studies of DEN230
n rhesus macaques did not demonstrate sufﬁcient attenuation.
EN230  was recovered from 100% of inoculated macaques and,
lthough the duration of viremia appeared somewhat lower com-
ared to wild-type virus (2.8 days vs 4.5 days), the mean peak titer
f DEN230  was not signiﬁcantly different from wild-type DENV-2
onga/74 (2.1 log10 PFU/mL vs 1.7 log10 PFU/mL, respectively) [40].
or this reason, DEN230  was not initially considered for further
valuation in humans as a vaccine candidate virus. However, these
haracteristics did suggest that the virus could be a suitable candi-
ate for use in a DHIM.
DEN230 was ﬁrst evaluated in a Phase I clinical trial in
ealthy, ﬂavivirus-naïve adults 18–50 years of age in Baltimore,
D  (Clinicaltrials.gov NCT01931176). The trial was  performed
nder an investigational new drug application reviewed by the
S Food and Drug Administration and approved by the Institu-
ional Review Board at Johns Hopkins University. Informed consent
as obtained in accordance federal and international regulations
21CFR50, ICHE6). Ten subjects received 103 PFU of DEN230 as a
ingle subcutaneous dose; four subjects received placebo as a con-
rol. All subjects returned to the clinic on study days 2, 4, 6, 8, 10,
2, 14, and 16 for evaluation by a clinician and to have blood drawn
or safety evaluation. Subjects returned on study days, 21, 28, 56,
nd 180 to be evaluated by a clinician and to have blood drawn
or immunological assessment. A complete blood count (CBC) with
ifferential and assays for virus titration from the serum were per-
ormed at each visit through study day 16. Virus detection in serum
as performed using direct titration and immunostain technique
s previously described [43].
able 2
iremia following infection with 103 PFU of DEN230.
Study No. of subjects Frequency of
viremia (%)
Mean peak titer
(log10 PFU/mL)
CIR286 10 100 2.5 ± 0.1 
CIR287  20 100 2.3 ± 0.1 LATV-challenge study
ted tetravalent vaccine.
DEN230 was recovered from all 10 subjects and induced a
mean peak titer of 2.5 log10 PFU/mL (range 1.5–3.3 log10 PFU/mL).
All subjects had detectable viremia on multiple days. The mean
day of onset of viremia was  day 4.6 and the mean duration
of viremia was 5.8 days (Table 2). Eighty percent of subjects
who received DEN230  developed a maculo-papular rash that
was graded as moderate in 50% occurrences. Forty percent of
DEN230 recipients developed neutropenia (absolute neutrophil
count <1000 mm−3); this was  graded as moderate (500–749 mm−3)
in 75% of occurrences. Although the high incidence of viremia
and rash induced by DEN230  indicated that the virus was not
suitable as a vaccine candidate, the fact that these clinical signs
were not accompanied by signiﬁcant dengue illness, made this
virus attractive as a challenge virus. For this reason, DEN230 was
then used to evaluate the protective efﬁcacy of a live attenuated
tetravalent dengue candidate vaccine in ﬂavivirus-naïve healthy
adults (CIR287, clinicaltrials.gov NCT02021968, manuscript sub-
mitted). On study Day 0, 24 subjects received vaccine and 24
subjects received a placebo. Six months later, all subjects were
challenged with rDEN230  and were followed clinically in the
same manner as described above. All 20 subjects who had received
placebo and returned for challenge became viremic following
challenge (mean peak titer = 2.3 log10 PFU/mL). The infectivity, inci-
dence and level of viremia, and clinical signs and symptoms
induced by DEN230  were very consistent between the two trials
(Tables 2–4 and 6). As noted previously, 80% of placebo recipi-
ents challenged with DEN230  developed a maculo-papular rash,
20% developed neutropenia, and 10% developed thrombocytopenia.
When compared to placebo administration on Day 0, the incidence
of viremia, rash, neutropenia, and retro-orbital pain were each
signiﬁcantly different (Table 3). As is observed in natural dengue
infection, CBC panels revealed markedly signiﬁcant decreases in
total white blood cell (WBC) and neutrophil counts following
administration of the challenge virus (Table 5). Mean WBC  counts
were 4.95 (±1.91) × 103L−1 in recipients of DEN230  and 6.04
(±1.82) × 103L−1 following placebo administration (p ≤ 0.00001).
Leukopenia was  only observed in DEN230  recipients. Similar dif-
ferences were noted in the absolute neutrophil count (ANC), with
a mean of 2892 (±1451) cells/mm3 among those that received
the virus and 3450 (±1655) for those that received placebo. This
decrease in mean ANC was highly signiﬁcant (p = 0.0005). Although
absolute thrombocytopenia (platelet count <120,000 L−1) was
observed in only two DEN230  recipients, platelet counts were
Viremia range
(log10 PFU/mL)
Mean day of onset Mean duration
(days)
1.5–3.3 4.6 ± 0.4 5.8 ± 0.6
1.5–2.9 4.7 ± 0.6 5.6 ± 0.5
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Table 3
Adverse events following administration of 103 PFU of rDEN230 compared to placebo.
Adverse event DEN230  CIR286, % (n = 10) DEN230 CIR287, % (n = 20) Placeboa, % (n = 28) p value (2-sided)b
Injection site
Erythema 0.0 0.0 0.0 n/a
Pain  0.0 0.0 8.3 0.4926
Tenderness 0.0 0.0 3.6 0.4828
Induration 0.0 0.0 0.0 n/a
Systemic
Viremia 100.0 100.0 0.0 <0.0001
Fever 0.0 0.0 0.0 n/a
Headache 60.0 25.0 17.9 0.0862
Rashc 80.0 80.0 0.0 <0.0001
Neutropeniad 40.0 20.0 0.0 0.0047
Elevated ALT 0.0 5.0 3.6 1.0000
Myalgia 20.0 20.0 7.1 0.2555
Arthralgia 20.0 5.0 0.0 0.1129
Retro-orbital pain 40.0 25.0 0.0 0.0020
Fatigue 50.0 15.0 14.3 0.3356
Elevated PT 10.0 0.0 14.3 0.1866
Elevated PTT 10.0 0.0 7.1 0.6053
Thrombocytopenia 0.0 10.0 0.0 0.4912
a Subjects who received DEN230 served as their own placebo controls as they had received placebo as dose 1 six months prior to receiving DEN230.
b p value is calculated for DEN230 recipients (n = 30) vs placebo.
c 10/24 (42%) rashes were graded as moderate.
d 5/8 (63%) neutropenia occurrences were graded as moderate (ANC = 500–749 mm−3).
Bolded ﬁndings represent virologic/clinical ﬁndings that occur consistently and with a signiﬁcantly higher incidence than controls in this model.
Table  4
Rash following infection with DEN230.
Study No. of subjects Frequency of rash (%) Mean day of onset Mean duration
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CIR287  20 80 
ighly signiﬁcantly decreased in this group relative to placebo
dministration (p < 0.00001). Signiﬁcant increases in liver enzymes
ere not observed following administration of either DEN230  or
lacebo.
DEN230 consistently induced viremia, rash, and neutropenia
n a high proportion of subjects without causing debilitating ill-
ess or signs of severe dengue (Table 6). The ability of this virus
o induce reproducible, objective ﬁndings of dengue infection in
 very high proportion of inoculated subjects without inducing
evere illness makes it attractive for use as a challenge virus. The
ffectiveness of a DENV vaccine or therapeutic can now be safely
valuated with statistical signiﬁcance in a relatively small number
f subjects. Additional DENV strains are being developed by the NIH
or use in the DHIM with the goal of identifying candidates able to
nduce consistent viremia and mild clinical signs and/or symptoms,
s demonstrated by DEN230,  in infected individuals.
. Dengue disease model
As part of their LATV dengue vaccine development program,
he Walter Reed Army Institute of Research (WRAIR) has evaluated
even different monovalent DENV strains for use as challenge
iruses (Table 7) [30,44–46]. Two of these viruses, DENV-1
5AZ5K and DEN-3 CH53489 (cl 24/28), were initially evaluated as
able 5
ematologic function test values in DEN230  and placebo recipients.
Test Post-challenge (n = 30) P
Mean ± SD Min/max M
WBC  count (×103/L) 4.95 ± 1.91 2.2/14.9 6
Absolute neutrophil count (/mm3) 2892 ± 1451 621/10300 3
Absolute monocyte Count (×103/L) 231 ± 238 2.3/909 
Platelets (×1000/L) 203 ± 52 103/391 
ALT  (units/L) 25.2 ± 13.6 4/84 279.4 ± 0.8 7.2 ± 1.3
9.6 ± 0.4 8.1 ± 0.7
candidate vaccine viruses; the others were evaluated speciﬁcally
for use as a challenge virus. The parent of DENV-1 45AZ5K was
obtained from a patient who developed mild dengue fever in
the western Paciﬁc in 1974 [46]. The virus was serially passaged
in fetal rhesus lung cells (FRhL) and chemically mutagenized
with 5-azacytidine. Although the DENV-1 45AZ5K produced only
limited viremia in rhesus macaques, when it was evaluated at a
dose of 4.5 log10 PFU in two  adults it induced signs and symptoms
of dengue fever (subjects 1 and 2 in Table 7). Interestingly, both
volunteers had previously received the YF17D vaccine and one had
previously received an inactivated tick-borne encephalitis vaccine.
DEN-3 CH53489 (cl 24/28) was derived from a DENV-3 virus
recovered from an 8-year old girl hospitalized with dengue fever
in Thailand [45]. The human isolate was  passaged four times in
AGMK cells and then seven additional passages in C6/36 mosquito
cells. A ﬁnal passage of the virus was  made in FRhL cells. The
resultant virus DEN-3 CH53489 (cl 24/28) demonstrated different
phenotypic markers, including small plaque size and temperature-
sensitive replication, which suggested reduced virulence in tissue
culture. However, when administered to two  healthy adult male
volunteers, both developed dengue fever-like illness (subjects 1
and 2 in Table 7). Again, both subjects had previously received
the YF17D vaccine. The remaining ﬁve viruses the WRAIR has
evaluated as potential challenge viruses were chosen because they
lacebo (n = 28) Mean change p-Value (t-test)
ean ± SD Min/max
.04 ± 1.82 2.6/5.6 −1.09 <0.00001
450 ± 1655 830/14030 −559 0.0005
225 ± 207 2.8/808 5.61 0.8
231 ± 62 126/415 −28.45 <0.00001
.61 ± 31.60 3/314 −2.44 0.5
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Table  6
Line listing of the clinical and virologic outcomes in recipients of DEN230.
Vol no. Age Gender Race Fever (T ≥ 38.4 ◦C) Rash (Days) Days viremia (Peak titera) Max  ALT (IU/mL) ANC nadirb (Day) Platelet nadirc (Day)
1 27 Female Black None None 4–10 (2.6) 35 (16) 1642 (11) 166 (10)
2  22 Male Black None 10–16 4–8 (1.5) 23 (17) 922 (14)e 130 (10)
3  45 Female Black None 11–21 4–8 (1.9) 36 (16) 1097 (10) 189 (14)
4  20 Male Black None None 4–10 (2.6) 52 (14) 695 (11) 145 (14)
5  26 Female White None 7–17 4–10 (2.7) 18 (14) 806 (11) 203 (14)
6  37 Male Black None 10–14 4–11 (2.5) 10 (8) 1123 (10) 156 (10)
7  22 Male Black None 11–14 7–8 (2.8) 13 (0) 1940 (14) 193 (11)
8  30 Female Black None 9–15 4–8 (3.3) 11(21) 592 (11) 140 (14)
9  31 Female Black None 12–15 7–11 (2.4) 10 (0) 1569 (11) 163 (11)
10  32 Female Black None 11–15 4–10 (2.7) 13 (10) 1283 (11) 184 (14)
11  26 Female White None 7–18 4–8 (2.8) 18 (14, 22) 1368 (14) 176 (14)
12  49 Female Black None 11–22 4–11 (2.6) 40 (22)f 3008 (14) 170 (8)
13  37 Male Black None 11–21 8–16 (1.5) 6 (0) 2800 (16) 182 (0)
14  36 Male Black None None 14–16 (1.9) 34 (22) 660 (10) 150 (10, 11)
15  50 Male Black None 10–22 4–11 (1.7) 14 (14) 3221 (16) 205 (14)
16  24 Male Black None 11–16 4–10 (2.8) 38 (0) 872 (11) 177 (16)
17  49 Male White None 14–18 3, 4d (2.2) 53 (21) 1288 (11) 103 (14)g
18 49 Male Black None 10–14 4–10 (2.0) 12 (21) 1388 (10) 152 (11)
19  24 Female Black None None 4–8 (2.7) 9 (16) 2039 (14) 242 (11)
20  29 Male Black None 8–21 7–11 (2.2) 34 (14) 653 (11) 208 (11)
21  26 Male Black None None 4–10 (2.6) 17 (7) 621 (14) 129 (0)
22  29 Male White None 10–17 6 (2.1) 34 (6) 1510 (13) 112 (14)
23  26 Female White None 8–18 3–8 (2.1) 26 (6) 1290 (10) 191 (13)
24  22 Male White None 8–15 6–8 (1.8) 84 (22) 1160 (13) 178 (13)
25  23 Male White None None 3–8 (1.9) 26 (16) 2690 (8) 200 (14)
26  21 Male White None 11–18 3–8 (2.3) 33 (22) 2380 (13) 222 (9)
27  24 Female White None 8–15 3–22 (2.9) 26 (6) 1600 (8) 131 (13)
28  22 Female White None 9–15 3–8 (2.7) 27 (14) 1130 (13) 207 (10)
29  45 Male White None 10–16 3–8 (2.7) 39 (14) 1330 (13) 162 (14)
30  29 Male White None 8–19 3–8 (2.2) 49 (16) 1560 (14) 157 (14)
a Log10 PFU/mL.
b Neutrophils/mm3.
c Platelets × 1000 L−1.
d This subject did not have blood drawn for virology on study days 7–10.
e Bolded values meet the deﬁnition of neutropenia (ANC < 1000 mm−3).
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ere earlier derivatives of candidate vaccine viruses that were
ound to be under-attenuated when evaluated in humans.
The primary objective of the WRAIR was to identify DENV
hat would cause dengue fever in infected individuals who  were
engue-naïve at challenge. Viruses that induced dengue fever
ould then be used to evaluate the protective efﬁcacy of the LATV
engue vaccines developed by WRAIR. Dengue fever was  deﬁned
s an illness with sustained fever (oral temperature >38 ◦C for
48 h); detectable concurrent dengue viremia by culture, and two
r more of the following: headache, myalgia, erythematous rash,
etro-orbital pain, arthralgia [30]. Subjects were monitored in an
npatient or hotel setting for a minimum of 14 days following infec-
ion. Many of the subjects had serial ultrasounds performed to
onitor for plasma leakage [29,44].
Of the seven viruses evaluated, two caused illness that met
rotocol-deﬁned dengue fever (DENV-1 45AZ5K and DENV-3
H53489 cl 24/28). These two viruses were later administered to
olunteers who had previously received a candidate live attenuated
etravalent dengue vaccine to determine the protective efﬁcacy of
he vaccine (subjects CD1-1, CD1-2, CD3-1, CD3-2, Table 7) [29].
he titer of DENV-1 45AZ5K used in this challenge study was found
o be approximately 50-fold lower than expected. DENV-1 34AZ5K
as recovered from 5/6 subjects; one control subject (CD1-1)
ailed to develop detectable viremia. The peak titer of virus, as
etermined by plaque assay (PFU/mL), was reported for only 2
ubjects and was 2.4 log10 PFU/mL and 2.7 log10 PFU/mL. DENV-3
H53489 (cl 24/28) caused dengue fever in all seven subjects to
hom it has been administered (Table 7). It induced rash in seven,
eutropenia in two, thrombocytopenia in two, and elevated ALT in
ne subject. One subject also developed perihepatic, perisplenic,and pericardial effusions post-infection. The peak titer of virus
as determined by plaque assay (PFU/mL) recovered from infected
subjects was not reported for any of the subjects. The peak titer of
virus by quantitative PCR was reported for the subjects who were
infectivity controls in the vaccine challenge study. The peak titers
for these subjects were 8.8 and 6.6 log10 genome equivalents/mL.
All of the DENV-2 and DENV-4 candidate challenge viruses
failed to meet the protocol deﬁnition of dengue fever. The two
DENV-2 candidates, DENV-2 S16803 (PDK 10) and DENV-2 PR159,
failed to induce fever in any of the three infected subjects how-
ever, all three subjects developed effusions post-infection (Table 7).
DENV-2 S16803 induced pleural effusion and ascites in one sub-
ject and a pericardial effusion in the second. DENV-2 PR159 failed
to induce detectable viremia in the one subject infected, how-
ever it did induce a perisplenic effusion in that subject. Why  these
viruses were able to induce signs of vascular leak despite very little
clinical illness is not clear. Cellular immune studies were not per-
formed as part of the trial and peak titers of virus post-infection
were not reported. Both of these viruses have been abandoned
for use in a challenge model. DENV-4 341750 (PDK 0) and DENV-
4 341750 (PDK 6) failed to induce a fever in any of the three
subjects to whom they were administered (Table 7). The three
subjects did not develop rash, neutropenia, or thrombocytope-
nia. The two  subjects who received DENV-4 341750 (PDK 6) did
not develop detectable viremia. The subject who  received DENV-4
341750 (PDK 0) had detectable viremia but the peak titer was not
reported. Three subjects received DENV-4 H241 (PDK 35). One  of
those subjects (#15) was febrile on three days however the days
were not consecutive so the deﬁnition of dengue fever was not
meant. This subject also developed a perisplenic effusion. The other
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Table 7
Dengue challenge viruses evaluated by the Walter Reed Army Institute of Research.
Virus/subject no. Dose (log10
PFU)
Fever days (TMax) Rash Neutropenia
(<1000 mm−3)
Thrombocyto-penia
(Nadir)a
Peak ALT Viremia (Max titer,
log10 PFU/mL)
Effusions
DENV-1 45AZ5K (PDK 0) [29,30,44,46]
9 (CH02-1-03) 4.2 4 days (39.2) Yes (12 days) No No 37 9–12 (NR) None
10  (CH02-01-04) 4.2 2 days (38.3) Yes (1 day) Yes (572 nadir) No 25 13–14 (NR) Perihepatic
CD1-1  3.0 21, 22 (39.4) Yes (20–22) No No 56 None None
CD1-2  3.0 19 (38.3) No No No 35 15–17 (NR) None
1b 4.5 9–13 (39.1) Yes (9–17) No No Wnld 1–12 (2.4) Not tested
2c 4.5 9–13 (39) Yes (8–17) No No Wnld 1–19 (2.7) Not tested
DENV-2 S16803 (PDK 10) [30]
2 (CH01-1-02) 5.1 None Yes (6 days) No Yes (88 K) 41 6–12 (NRe) Pleural effusion, ascites
4  (CH01-1-04) 5.1 None Yes (4 days) No No 33 7–10, 12, 13 (NR) Pericardial effusion,
Gallbladder wall thickening
DENV-2  PR159 [30]
12 (CH02-1-06) 4.8 None No No No 51 None Perisplenic
DENV-3 CH53489 (cl 24/28) [29,30,44,45]
1b 4.3 5–9 (NR) Yes (NR) NR Yes (58 K) NR 3–10 (NR) Not tested
2b 4.3 6–9 (NR) Yes (NR) NR No NR 3–9 (NR) Not tested
6  (CH01-1-06) 4.5 4 days (38.9) Yes (4 days) No No 39 2–8 (NR) None
7  (CH02-1-01) 4.5 4 days (39.6) Yes (7 days) No No 64 4–9 (NR) None
11  (CH02-1-05) 4.7 3 days (38.7) Yes (4 days) Yes (525 nadir) No 81 3–8 (NR) Perihepatic, perisplenic,
pericardial
CD3-1  5.0 6–9 (38.4) Yes (1 day) Yes (600 nadir) Yes (92 K) 367 4–9 (NR)f None
CD3-2  5.0 Day 2 (38.7) Yes (3 days) No No 49 4–8 (NR)g None
DENV-4 341750 (PDK 6) [30,44]
1 (CH01-1-01) 6.0 None No No No 94 None None
5  (CH01-1-05) 6.0 None No No No 43 None None
DENV-4 341750 (PDK 0) [30,44]
14 CH02-1-08 5.9 1 day (37.9)h No No No 42 7–12 (NR) Perihepatic
DENV-4 H241 (PDK 35) [30,44,48]
3 4.4 None Yes (8 days) NR NR ∼100 6–10 (1.5) Not tested
4  4.4 None Yes (8 days) NR NR ∼100 5–9 (2.0) Not tested
15  (CH01-1-09) 3.6 3 days (38.3)i Yes (7 days) No No 50 3–10 (NR) Perihepatic
a Thrombocytopenia was  deﬁned as a platelet count <120,000.
b Previously received YF-17D vaccine.
c Previously received YF-17D vaccine and inactivated tick-borne encephalitis vaccine.
d Wnl  = within normal limits, absolute value not given.
e NR = not reported.
f 8.8 log10 genome equivalents.
g 6.6 log10 genome equivalents.
h Did not meet criteria for dengue fever.
i Fever days were non-consecutive and thus did not meet criteria for dengue fever.
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wo subjects did not develop fever. All three subjects developed
ash and had detectable virus recovered, the peak titer of which was
eported in two (1.5 log10 PFU/mL and 2.0 log10 PFU/mL). Two of the
hree subjects developed elevations in the liver transaminase ALT
f approximately 100 IU. Investigators at WRAIR concluded that
ENV-4 341750 (PDK 0) and DENV-4 H241 may  warrant further
valuation as potential DENV-4 challenge viruses [30].
. Summary
The DHIM could be a very useful tool for the development
f both dengue vaccines and dengue therapeutics. Two different
odels are currently being used to assess vaccine efﬁcacy. The
EN230 DHIM developed by the NIH utilizes viremia as the
rimary endpoint to assess vaccine efﬁcacy. This model induces
engue infection that is characteristic of the majority of dengue
nfections; one that induces mild clinical signs/symptoms and
ower levels of viremia. The frequency and level of viremia induced
y DEN230  is highly reproducible and allows for differences in
he titer of virus to be easily detected in a statistically signiﬁcant
anner. Because subjects do not develop frank dengue fever, they
an be followed in an outpatient setting. This allows larger cohorts
f subjects to be enrolled simultaneously and at lower cost. Because
ubjects do not develop dengue fever or severe disease, the model
ay  not be useful to study the pathogenesis of dengue vascular leak
yndrome. The efﬁcacy of some therapeutics may  also not be able
o be evaluated in this model if reduction of viremia is not a suitable
ndpoint for the therapeutic. The NIH has developed and manufac-
ured DEN330  under cGMP for use as a DENV3 in the DHIM. This
irus will be evaluated in a safety study in healthy, ﬂavivirus-naïve
dult volunteers in 2015. In addition, suitable DENV-1 and DENV-4
trains are being identiﬁed for manufacture and clinical evaluation
or use in the DHIM with the goal of identifying viruses that could
e used to assess the protection afforded by LATV dengue vaccine
gainst each of the four DENV serotypes.
WRAIR has identiﬁed DENV-1 45AZ5K and DENV-3 CH53489
cl 24/28) as candidate DENV-1 and DENV-3 challenge viruses in
 dengue disease model. A new lot of DENV-1 45AZ5K has been
anufactured under cGMP and will be tested in an inpatient dose-
anging study to identify the dose that most consistently induces
engue fever (NCT02372175). Because these viruses induce dengue
ever, the studies must be performed in an inpatient setting to
nsure appropriate clinical evaluation and management. In addi-
ion to evaluating vaccine efﬁcacy, this model may  prove useful in
etter understanding the pathogenesis of the dengue vascular leak
yndrome and to possibly evaluate the ability of a dengue vaccine
r therapeutic to modify the course of illness. Both models have the
otential to be very useful tools for minimizing the risk of dengue
accine development and down-selecting candidate dengue vac-
ines prior to performing large efﬁcacy studies in dengue endemic
reas. This will help to reduce the potential of introducing a poorly
ffective vaccine to endemic populations, thereby decreasing the
otential long-term safety concerns that accompany a partially
ffective dengue vaccine.
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